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Abstract  
Fasciola’s excretory-secretory material comprises chiefly cathepsin B and cathepsin L. These cysteine proteases are proposed as
major mediators of parasitism, and are considered targets for vaccination. In order to assess the vaccine efficacy of these enzymes, 
single and multivalent recombinant protein vaccinations of adult-stage F. hepatica cathepsin L5, metacercarial-stage F. gigantica 
cathepsin L1g and juvenile-stage F. hepatica cathepsin B were analysed in rats against F. hepatica challenge infection. The 
protective efficacy of anti-fluke vaccines was evaluated in terms of parasitological parameters (recovered fluke burden, fluke body 
size and wet weight) and pathological changes (liver damage score) in rats. The rats vaccinated with recombinant proteins were 
shown to have significantly fewer and smaller flukes than the control rats. A maximum protection of 83% was seen in the group 
vaccinated with a combination of cathepsin B and cathepsin L5. 
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1. Introduction 
Fasciola hepatica and F. gigantica cause liver fluke disease in ruminants and humans. This emerging human 
pathogen is highly prevalent in South American countries, Northern Iran and Egypt (1). These two major parasite 
species are prevalent in temperate and tropical regions respectively, which means that infection can occur worldwide. 
Though anti-parasitic drug treatment is effective against disease, emerging drug resistant strains leads to the need for 
the development of a viable vaccine. Although much research into vaccination against the parasite has been undertaken, 
no commercial vaccine is as yet available.  
Cysteine proteases are common virulence mediaters of parasites, and are produced by all stages of the fluke life 
cycle. The mediate biological functions including excystment, tissue invasion and immune evasion (2). Adult fluke 
cathepsin L and Newly Excysted Juvenile (NEJ) cathepsin B are the prominent proteolytic enzymes of their respective 
ES materials. F. hepatica cathepsin L5 (3, 4), cathepsin B (5-8) and F. gigantica cathepsin L1 (9) are promising targets 
for vaccines against Fasciola infection and are evaluated here.  
In order to assess cysteine protein vaccine potential, recombinant protein expression is usually desirable. The yeast 
expression system has been a useful tool for the functional expression of cathepsin L1 and L2 (10, 11), cathepsin L5 
and cathepsin B (5, 7). Here we evaluate the vaccine efficacy of the multivalent vaccines using yeast-expressed 
recombinant protein proteases derived from juvenile and adult-stage liver fluke in the rat fasciolosis model. Some of 
the data presented here was recently published by Jayaraj and colleagues (12). 
2. Recombinant vaccine production, vaccination and challenge infection 
The expression and purification of cathepsin B, cathepsin L5 and cathepsin L1g from S. cerevisiae BJ 3505 cells 
were preceded according to Law et al. (2003) and Smooker et al. (2000) (4, 7). The expressed proteins were purified by 
ords: Cathepsin proteases, Multivalent vac ines, Fasciola
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Ni-NTA affinity chromatography and eluted fractions were used for vaccine formulations (13). Sprague Dawley male 
rats were used in the vaccination experiment for testing yeast expressed protein vaccines, and they were aged six weeks 
at the time of vaccination and 12 weeks at the time of parasite challenge. Seven to nine rats were used per vaccination 
group and the trial was assessed by the Monash University animal ethics committee, Australia. Rats were vaccinated 
with 20 µg of recombinant proteins in 200 uL 0.9% saline adjuvented with 1 mg/mL Quil A. Control rats received Quil 
A in 0.9% saline only. The rats were vaccinated thrice at two weekly intervals via the intraperitoneal route. For the 
parasite challenge, metacercarial cysts (infective stage) from laboratory Lymnae tomentosa snail cultures (Macarthur 
Agricultural Institute, Menangle, NSW, Australia) were used. At week 12 (2 weeks after the third vaccination) rats 
were infected orally using a gavage needle with 25 metacercariae in 1 mL 0.4% carboxy methyl cellulose (Sigma). 
3. Necropsy and analysis of pathological and parasitological parameters 
Vaccinated rats were humanely sacrificed at week 20 (eight weeks after infection), and their livers removed. 
Pathological lesions of livers were observed by the naked eye and liver damage determined (blind scoring). The 
severity and the intensity of lesions was quantitatively scored from 0 to 5 (14). Live adult flukes inside the lumen of 
bile duct were dissected out by using forceps and the whole liver was dissected, incubated in saline at 370 C for 1 hour 
and filtered through a 200 ȝM mesh sieve for detection of flukes. The influence of recombinant vaccines on the fluke 
recovery, body, size and wet weight are important factors of protection (15-17). The body lengths from head to tail and 
body width of each worm from all vaccinated and control rat groups were measured using a dissection microscope with 
a millimetre scale (18, 19). 
4. Results and Discussion 
The vaccinated rats were sacrificed 8 weeks after challenge infection and the extracted livers assessed for the 
damage scores (Table 1A). In the control rat group, four rat livers had the high score of 4 (mean 3.3), indicative of 
damage (Figure 1). All groups containing either cathepsin B or L5 have a significantly reduced damage score compared 
to the control group, with the divalent B/L5 group having the least mean damage, at 0.9. The mean liver fluke burden 
from the vaccinated rats is also given in Table 1A. In rats vaccinated with any combination of recombinant proteins, 
recovered numbers of liver flukes are significantly lower than in control rats. Recovered liver fluke length and width, 
total mass of recovered flukes and liver damage are the major factors often used to indicate the protection against the 
severity of parasite infection (17, 18). The liver fluke body length, width (shown in Figure 1) and wet weights are 
reduced in the vaccinated groups (Table 1B). These results show that vaccination with the multivalent cathepsin B/L5 
leads to less liver damage, lower fluke numbers and the lowest mean wet weight compared to control rats.  
Table 1. A. The experimental design of the vaccine trial and analysis of mean liver damage scores and mean Fluke burden in infected rats.  
P value a=<0.05, b=<0.01, c=<0.001. 
Vaccine group 
Rats/ 
group Antigen dose Liver damage 
Fluke 
Burden 
1 Control 8 0 µg 3.3 ± 1.0 4.38 ± 0.74 
2 Cat B 8 20 µg 1.3 ± 0.8b 1.75 ± 1.04c
3 Cat L5 8 20 µg 1.3 ± 1.1b 2.13 ± 0.35c
4 Cat L1g 9 20 µg 1.9 ± 1.1 2.22 ± 1.3*
5 Cat B/L5 8 10 µg of each antigen 0.9 ± 1.0c 0.75 ± 0.46c
6 Cat B/L1g 7 10 µg of each antigen 1.9± 1.0 1.71 ± 0.95c
7 Cat L5/L1g 8 10 µg of each antigen 1.6± 1.1a 1.75 ± 1.16c
8 Cat B/L5/L1g 7 6.6 µg of each antigen 1.9± 1.3 1.85 ± 1.35c
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B. Body size and mean wet weight of recovered liver flukes at necropsy.
Vaccine group Mean body length (mm) Mean body Width (mm) Mean wet weight (mg) 
1 Control 23.6 ± 3.41 10.48  ± 3.49 120.6 ± 31.1 
2 Cat B 7.86 ± 2.72# 4.33  ± 1.58c 44.06 ± 27.8c
3 Cat L5 10.58 ± 2.15# 4.82  ± 1.5c 50.00 ± 17.2c
4 Cat L1g 12.15 ± 3.18# 5.5  ± 1.19c 68.65 ± 29.7c
5 Cat B/L5 4.00 ± 2.5# 2.25  ± 1.38c 28.87 ± 18.7c
6 Cat B/L1g 9.53 ± 3.5# 5.61  ± 2.02c 45.06 ± 21.6c
7 Cat L5/L1g 11.00 ± 5.16# 5.4  ± 2.24c 57.93 ± 24.8c
8 Cat B/L5/L1g 11.07 ± 4.15# 5.53  ± 1.8c 58.15 ± 32.9c
This result indicates liver fluke development was retarded in the vaccinated groups. It may be that a fluke vaccine 
does not need to induce sterile immunity, but reduce the pathology to a level that is tolerated by the animal. A reduction 
in fluke burdens will also reduce the numbers of eggs passed by infected animals, reducing pasture contamination. Our 
study indicates that juvenile stage-specific recombinant proteins (B, L1g) are able to mediate immunity to liver fluke 
infection, but that protection is greatest when a juvenile stage protease (cathepsin B) is used in concert with an adult 
stage protease, L5. The greatest protection (83%) was afforded by a vaccine with both these cathepsins, and two rats in 
this group did not have any detectable liver flukes. This indicates that multivalent vaccination is probably optimal for 
this large, multicellular parasite, and this may be a general feature of such vaccine strategies. 
In conclusion, the protective immunity elicited by recombinant protein vaccination appears to evoke effector and 
memory responses against infection. We have shown that such vaccination induces strong humoral responses (12), 
although the precise effecter mechanisms leading to fluke control have not been elucidated. That a cocktail of juvenile 
and adult stage Fasciola recombinant proteins induced the better protective immunity than individual protein alone 
indicates that stage specific, multivalent recombinant vaccines against parasites may feasible. 
Figure 1: Analysis of liver damage and F. hepatica parasite size in control and vaccinated rats at necropsy. 
Two representative livers are shown here: a liver from a control rat (first photograph), showing enlarged lobes with 
necrotic lesions (liver damage score 4); Photograph two, a Cathepsin B vaccinated rat liver showing a healthy, pliable 
and soft glassy appearance with minimal damage (liver damage score 0.5). The right hand panel shows a representative 
large size fluke from a control rat and a smaller fluke from a protein vaccinated. 
R. Jayaraj et al. / Procedia in Vaccinology 2 (2010) 82–85 85
5. References 
1. Esteban JG, Gonzalez C, Curtale F, Munoz-Antoli C, Valero MA, Bargues MD, et al. Hyperendemic fascioliasis associated with 
schistosomiasis in villages in the Nile Delta of Egypt. Am J Trop Med Hyg 2003 Oct;69(4):429-37. 
2. Sajid M, McKerrow JH. Cysteine proteases of parasitic organisms. Mol Biochem Parasitol 2002 Mar;120(1):1-21. 
3. Irving JA, Spithill TW, Pike RN, Whisstock JC, Smooker PM. The evolution of enzyme specificity in Fasciola spp. J Mol Evol 2003 
Jul;57(1):1-15. 
4. Smooker PM, Whisstock JC, Irving JA, Siyaguna S, Spithill TW, Pike RN. A single amino acid substitution affects substrate specificity in 
cysteine proteinases from Fasciola hepatica. Protein Sci 2000 Dec;9(12):2567-72. 
5. Beckham SA, Law RH, Smooker PM, Quinsey NS, Caffrey CR, McKerrow JH, et al. Production and processing of a recombinant Fasciola 
hepatica cathepsin B-like enzyme (FhcatB1) reveals potential processing mechanisms in the parasite. Biol Chem 2006 Aug;387(8):1053-61. 
6. Kennedy NJ, Spithill TW, Tennent J, Wood PR, Piedrafita D. DNA vaccines in sheep: CTLA-4 mediated targeting and CpG motifs enhance 
immunogenicity in a DNA prime/protein boost strategy. Vaccine 2006 2006/2/13;24(7):970-9. 
7. Law RH, Smooker PM, Irving JA, Piedrafita D, Ponting R, Kennedy NJ, et al. Cloning and expression of the major secreted cathepsin 
B-like protein from juvenile Fasciola hepatica and analysis of immunogenicity following liver fluke infection. Infect Immun 2003 
Dec;71(12):6921-32. 
8. Meemon K, Grams R, Vichasri-Grams S, Hofmann A, Korge G, Viyanant V, et al. Molecular cloning and analysis of stage and tissue-specific 
expression of cathepsin B encoding genes from Fasciola gigantica. Molecular and Biochemical Parasitology 2004 2004/7;136(1):1-10. 
9. Grams R, Vichasri-Grams S, Sobhon P, Upatham ES, Viyanant V. Molecular cloning and characterization of cathepsin L encoding genes from 
Fasciola gigantica. Parasitol Int 2001 Jul;50(2):105-14. 
10. Dowd AJ, Smith AM, McGonigle S, Dalton JP. Purification and characterisation of a second cathepsin L proteinase secreted by the parasitic 
trematode Fasciola hepatica. Eur J Biochem 1994 Jul 1;223(1):91-8. 
11. Roche L, Dowd AJ, Tort J, McGonigle S, MacSweeney A, Curley GP, et al. Functional expression of Fasciola hepatica cathepsin L1 in 
Saccharomyces cerevisiae. Eur J Biochem 1997 Apr 15;245(2):373-80. 
12. Jayaraj R, Piedrafita D, Dynon K, Grams R, Spithill TW, Smooker PM. Vaccination against fasciolosis by a multivalent vaccine of stage-specific 
antigens. Vet Parasitol 2009 Mar 23;160(3-4):230-6. 
13. Jayaraj R, Piedrafita D, Dynon K, Grams R, Spithill TW, Smooker PM. Vaccination against fasciolosis by a multivalent vaccine of stage-specific 
antigens. Vet Parasitol 2009;160(3-4):230-6. 
14. Raadsma HW, Kingsford NM, Suharyanta, Spithill TW, Piedrafita D. Host responses during experimental infection with Fasciola gigantica or 
Fasciola hepatica in Merino sheep I. Comparative immunological and plasma biochemical changes during early infection. Vet Parasitol 2007 
Feb 28;143(3-4):275-86. 
15. Nambi PA, Yadav SC, Raina OK, Sriveny D, Saini M. Vaccination of buffaloes with Fasciola gigantica recombinant fatty acid binding protein. 
Parasitol Res 2005 Sep;97(2):129-35. 
16. Ramajo V, Oleaga A, Casanueva P, Hillyer GV, Muro A. Vaccination of sheep against Fasciola hepatica with homologous fatty acid binding 
proteins. Vet Parasitol 2001 May 9;97(1):35-46. 
17. Valero MA, De Renzi M, Panova M, Garcia-Bodelon MA, Periago MV, Ordonez D, et al. Crowding effect on adult growth, pre-patent period and 
egg shedding of Fasciola hepatica. Parasitology 2006 Oct;133(Pt 4):453-63. 
18. Valero MA, Panova M, Comes AM, Fons R, Mas-Coma S. Patterns in size and shedding of Fasciola hepatica eggs by naturally and
experimentally infected murid rodents. J Parasitol 2002 Apr;88(2):308-13. 
19. Valero MA, Panova M, Mas-Coma S. Phenotypic analysis of adults and eggs of Fasciola hepatica by computer image analysis system. J
Helminthol 2005 Sep;79(3):217-25. 
